388 related articles for article (PubMed ID: 32850308)
1. Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma.
Lacouture ME; Anadkat MJ; Ballo MT; Iwamoto F; Jeyapalan SA; La Rocca RV; Schwartz M; Serventi JN; Glas M
Front Oncol; 2020; 10():1045. PubMed ID: 32850308
[No Abstract] [Full Text] [Related]
2. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z
JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225
[TBL] [Abstract][Full Text] [Related]
3. Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region.
Anadkat MJ; Lacouture M; Friedman A; Horne ZD; Jung J; Kaffenberger B; Kalmadi S; Ovington L; Kotecha R; Abdullah HI; Grosso F
Front Oncol; 2022; 12():975473. PubMed ID: 36703794
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study.
Bokstein F; Blumenthal D; Limon D; Harosh CB; Ram Z; Grossman R
Front Oncol; 2020; 10():411. PubMed ID: 32373508
[No Abstract] [Full Text] [Related]
5. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R
JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z; Kim CY; Hottinger AF; Idbaih A; Nicholas G; Zhu JJ
Front Oncol; 2021; 11():671972. PubMed ID: 34692470
[TBL] [Abstract][Full Text] [Related]
7. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
Lacouture ME; Davis ME; Elzinga G; Butowski N; Tran D; Villano JL; DiMeglio L; Davies AM; Wong ET
Semin Oncol; 2014 Jun; 41 Suppl 4():S1-14. PubMed ID: 24794308
[TBL] [Abstract][Full Text] [Related]
8. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
[TBL] [Abstract][Full Text] [Related]
9. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
10. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W
J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976
[TBL] [Abstract][Full Text] [Related]
11. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Burri SH; Gondi V; Brown PD; Mehta MP
Am J Clin Oncol; 2018 Feb; 41(2):191-196. PubMed ID: 28832384
[TBL] [Abstract][Full Text] [Related]
12. The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts.
Oberheim-Bush NA; Shi W; McDermott MW; Grote A; Stindl J; Lustgarten L
J Neurooncol; 2022 Jul; 158(3):453-461. PubMed ID: 35639236
[TBL] [Abstract][Full Text] [Related]
13. Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies.
Wang Y; Pandey M; Ballo MT
Oncologist; 2019 Dec; 24(12):e1426-e1436. PubMed ID: 31444292
[TBL] [Abstract][Full Text] [Related]
14. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma.
Miller R; Song A; Ali A; Niazi M; Bar-Ad V; Martinez N; Glass J; Alnahhas I; Andrews D; Judy K; Evans J; Farrell C; Werner-Wasik M; Chervoneva I; Ly M; Palmer J; Liu H; Shi W
Front Oncol; 2022; 12():896246. PubMed ID: 35574391
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of Treating High Grade Gliomas in Children with Tumor-Treating Fields: A Case Series.
Crawford J; Saria MG; Dhall G; Margol A; Kesari S
Cureus; 2020 Oct; 12(10):e10804. PubMed ID: 33163308
[TBL] [Abstract][Full Text] [Related]
16. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
[TBL] [Abstract][Full Text] [Related]
17. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
[TBL] [Abstract][Full Text] [Related]
18. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
19. First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis.
Kassubek R; Mathieu R
Brain Sci; 2022 Apr; 12(4):. PubMed ID: 35448029
[TBL] [Abstract][Full Text] [Related]
20. Tumor treating fields: a new frontier in cancer therapy.
Davies AM; Weinberg U; Palti Y
Ann N Y Acad Sci; 2013 Jul; 1291():86-95. PubMed ID: 23659608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]